– USA, CA – Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a global insulin delivery and diabetes technology company, today announced the appointments of Myoung Cha and Joao Malagueira to its Board as independent directors, effective June 15, 2022.
“We welcome Joao and Myoung to our Board of Directors at this exciting stage in Tandem’s evolution. Joao’s extensive international experience brings tremendous value to our Company as we continue to expand our global reach, and Myoung’s strategic experience in leading-edge consumer technology at large companies will be invaluable as we advance our product pipeline,” said CEO, John Sheridan.
About Myoung Cha
Mr. Cha has more than 17 years of global experience across the healthcare value chain. Mr. Cha currently serves as President and CSO at Carbon Health where he leads the omnichannel care model and the device-enabled home care operations. Before joining Carbon Health in June 2021, he served as Head of Health Strategic Initiatives at Apple from August 2015 to May 2021 where he developed and led product initiatives and global strategic partnerships. Earlier in his career, Mr. Cha was a Principal and Co-Leader of the West Coast Strategy and Corporate Finance Practice as well as Co-Leader of the Healthcare Investor Practice at McKinsey & Company.
Mr. Cha holds a JD from Harvard Law School, an MBA from Harvard Business School, and an AB in Biochemical Sciences from Harvard College.
About Joao Malagueira
Mr. Malagueira brings more than 25 years of experience in diabetes, medical devices, and diagnostics solutions businesses with global corporations. Mr. Malagueira is currently VP for three divisions at Hologic and is responsible for the entire portfolio in the EMEA. Before starting this role in January 2019, he served as International Vice President, for EMEA and Canada, for the Hologic Diagnostics Solutions division, from June 2015 to December 2018. He possesses extensive experience and proven success with go-to-market models and strategies in Europe, Africa, CIS, and the Middle East. Before Hologic, Mr. Malagueira enjoyed more than 15 years at Johnson & Johnson, in commercial leading roles across EMEA, where he led successful turnarounds and market share growth of the diabetes solutions businesses, LifeScan and Animas.
Mr. Malagueira holds an MBA and an Advanced Degree in Marketing from Catolica Lisbon School of Business and Economics. He holds an MS in Pharmaceutical Sciences and Clinical Analysis from the University of Lisbon.
About Tandem Diabetes Care, Inc.
Tandem Diabetes Care, Inc., a global insulin delivery and diabetes technology company based in San Diego, California, creates new possibilities for people living with diabetes, their loved ones, and healthcare providers through a positively different experience. The Company’s human-centered approach to design, development, and support delivers innovative products and services for people who use insulin. Tandem manufactures and sells the t: slim X2 insulin pump with Control-IQ technology.
For more information: https://www.tandemdiabetes.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.